|
Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors Clinical research trials and Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors. Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors clinical trial. Participants frequently obtain the most expert healthcare available for their Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors  Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors
For Condition: Advanced Solid Tumors
Status: Recruiting
Sponsor(s): Eisai Medical Research Inc ,
Synopsis: To determine the maximum tolerated dose of E7389 when adminstered on Day 1 of a 21-day cycle to patients with advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Patients must have a histologically or cytologically confirmed and measurable advanced solid tumor that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy) - Patients may have received prior chemotherapy (limit of two prior chemotherapy regimens) - Patients must be aged > 18 years - Patients must have a Karnofsky Performance Status (Appendix IV) of > 70% - Patients must have a life expectancy of > 3 months - Patients must have adequate renal function as evidenced by serum creatinine <1.5mg/dL or creatinine clearance > 60mL/minute - Patients must have adequate bone marrow function as evidenced by absolute neutrophil count > 1,500/µL and platelets > 100,000/µL - Patients must have adequate liver function as evidenced by bilirubin < 1.5mg/dL and alanine transaminase (ALAT) and aspartate transaminase (ASAT) < 2 times the upper limits of normal - Patients must be willing and able to comply with the study protocol for the duration of the study - Patients must give written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice Exclusion Criteria - Patients who have received chemotherapy within three weeks (six weeks if nitrosoureas were received) of E7389 treatment start - Patients who have not recovered from any chemotherapy related or other therapy related toxicity at study entry - Patients who require therapeutic doses of anti-coagulant therapy (eg, Coumadin, heparin, low molecular weight heparin). Low doses of anticoagulants used for patency (eg, lines, catheters,ports) are permitted. - Women who are pregnant or breastfeeding. Women of childbearing potential with either a positive pregnancy test at Screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential) - Fertile men who are not willing to use contraception or fertile men with a female partner who is not willing to use contraception - Patients who have not successfully completed local therapy for previously treated central nervous system (CNS) metastases and who have not been discontinued from corticosteriods for at least four weeks before starting treatment with E7389. Patients with asymptomatic brain metastases who have no evidence of midline shift on CT scan or MRI may be enrolled without initiation of local therapy for the CNS metastases. In this case, a repeat scan must be performed within four weeks of the original scan to ensure that disease progression is not occurring. - Patients who have tested positive for HIV - Patients with severe uncontrolled intercurrent illness/infection (excluding malignancies) - Patients with cardiovascular impairment - Patients with organ allografts - Patients who have received investigational drugs, including immunotherapy, gene therapy, hormone therapy, or other biologic therapy; anti-neoplastic therapy; or radiation therapy (other than required for palliation) within three weeks of E7389 treatment start - Patients who have had major surgery within four weeks of E7389 treatment start without a full recovery - Patients with a hypersensitivity to Halichondrin B and/or Halichondrin B-like compounds - Patients with other significant disease that, in the Investigator’s opinion, would exclude the patient from the study
Total Enrollment: 35
Location and Contact Information:
California *Recruiting*
Santa Monica, California, 90404
United States
Recruiting
New Jersey *Recruiting*
New Brunswick, New Jersey, 08903
United States
Recruiting
Additional Information:
Study ID Numbers: E7389-A001-102; BOLD,E7389
Study Start Date: August 2003
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00069277
Other Advanced Solid Tumors Studies:
1. Study of E7389 in Patients with Advanced Solid Tumors
2. A Bioequivalence Study Of Two Oral Formulations Of An Investigational Drug In Patients With Advanced Solid Tumors.
3. Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors
Related Studies:
Other Advanced Solid Tumors Clinical Trials
Other New Jersey Clinical Trials
Other New Brunswick Clinical Trials
Study of E7389 Adminstered Once Every 3 Weeks In Patients With Advanced Solid Tumors
|
|
|
|
|
|
|
|
